EUCTR2013-005456-15-FR进行中（未招募）不适用
A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients with Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC) - GEIS-32
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Written informed consent
- •- Age = 18 years
- •- Centrally confirmed histologic diagnosis of SFT or EMC
- •- ECOG PS <2
- •- Measurable disease
- •- Maximum of 4 prior metastatic chemotherapy lines
- •- Able to swallow
- •- Adequate laboratory examinations
- •- Effective contraception
- •- Adequate Left Ventricular Ejection Fraction
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •- Prior malignancy
- •- active Central Nervous System metastasis
- •- Prior antiangiogenic agents
- •- Clinically significant gastrointestinal abnormalities with bleeding or malabsorption risk
- •- QTc > 480 msec
- •- History of major cardiovascular condition
- •- Poorly controlled hypertension
- •- bleeding risk or tumor lesions associated with bleeding risk
- •- concomittant prohibited treatment
- •- ongoing previous toxicity
研究者
相似试验
进行中（未招募）
1 期
A phase II trial of pazopanib drug given to patients with solitary fibrous tumor (SFT) and extraskeletal myxoid chondrosarcoma (EMC) that cannot be removed with surgery or having metastasisPatients with unresectable, locally advanced or metastatic solitary fibrous tumor (SFT) or extraskeletal myxoid chondrosarcoma (EMC)EUCTR2013-005456-15-ITGrupo Español de Investigación en Sarcomas70
进行中（未招募）
不适用
A phase II trial of pazopanib drug given to patients with solitary fibrous tumor (SFT) and extraskeletal myxoid chondrosarcoma (EMC) that cannot be removed with surgery or having metastasisPatients with unresectable, locally advanced or metastatic solitary fibrous tumor (SFT) or extraskeletal myxoid chondrosarcoma (EMC)EUCTR2013-005456-15-ESGrupo Español de Investigación en Sarcomas70
进行中（未招募）
1 期
A Phase II Study Investigating Upfront Pazopanib in Metastatic Clear Cell Renal Cancer [PANTHER] - PANTHER (version 6, 23 March 2012)EUCTR2009-016675-29-GBQueen Mary university of London104
已完成
2 期
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid ChondrosarcomaExtraskeletal Myxoid ChondrosarcomaSolitary Fibrous TumorNCT02066285Grupo Espanol de Investigacion en Sarcomas96
已完成
2 期
Phase II randomized clinical trial of Pazopanib alone and Pazopanib plus Gemcitabine in relapsed or metastatic soft tissue sarcomarelapsed or metastatic soft tissue sarcomaC49Malignant neoplasm of other connective and soft tissueDRKS00003139niversitätsklinikum Halle (Saale)90